Evidence map›Paper›PMID 36923239›Full record

ArticleJHEP reports : innovation in hepatology2023

Protective potential of the gallbladder in primary sclerosing cholangitis.

Nora Cazzagon, Ester Gonzalez-Sanchez, Haquima El-Mourabit, Dominique Wendum, Dominique Rainteau, Lydie Humbert, Christophe Corpechot, Olivier Chazouillères, Lionel Arrivé, Chantal Housset and 1 more

Open access · goldFull text read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Ultrasound for the Detection of Gallbladder Malignancy in Primary Sclerosing Cholangitis.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  5. Review
  6. Article
  7. [Primary sclerosing cholangitis-Diagnosis and treatment 2024].Innere Medizin (Heidelberg, Germany) · 2024
    Review
  8. Primary Sclerosing Cholangitis: Diagnostic Criteria.Tomography (Ann Arbor, Mich.) · 2024
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Nora CazzagonSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
Ester Gonzalez-SanchezSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
Haquima El-MourabitSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
Dominique WendumSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
Dominique RainteauSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
Lydie HumbertSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
Christophe CorpechotSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
Olivier ChazouillèresSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
Lionel ArrivéAssistance Publique-Hôpitaux de Paris (AP-HP). Sorbonne Université. Department of Radiology, Saint-Antoine Hospital, Paris, France.
Chantal HoussetSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
Sara LemoinneSorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
Inserm · FRSorbonne Université · FRUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Gallbladder enlargement is common in patients with primary sclerosing cholangitis (PSC). The gallbladder may confer hepatoprotection against bile acid overload, through the sequestration and cholecystohepatic shunt of bile acids. The aim of this study was to assess the potential impact of the gallbladder on disease features and bile acid homeostasis in PSC. Methods: Patients with PSC from a single tertiary center who underwent liver MRI with three-dimensional cholangiography and concomitant analyses of serum bile acids were included. Gallbladder volume was measured by MRI and a cut-off of 50 ml was used to define gallbladder enlargement. Bile acid profiles and PSC severity, as assessed by blood tests and MRI features, were compared among patients according to gallbladder size (enlarged Results: Sixty-one patients with PSC, all treated with ursodeoxycholic acid (UDCA), were included. The gallbladder was enlarged in 30 patients, whereas 11 patients had been previously cholecystectomized. Patients with enlarged gallbladders had significantly lower alkaline phosphatase, a lower tauro- Conclusion: Altogether, our findings indicate that the gallbladder fulfills protective functions in PSC. Impact and implications: In patients with primary sclerosing cholangitis (PSC), gallbladder status impacts on bile acid homeostasis and disease features. We found evidence of lessened bile acid toxicity in patients with PSC and enlarged gallbladders and of increased disease severity in those who were previously cholecystectomized. In the

Indexed as

ABC, ATP-binding cassette transporterAbcb4 knockout miceBA, bile acidBile acidsC4, 7α-hydroxy-4-cholesten-3-oneCFTR, cystic fibrosis transmembrane conductance regulatorCholecystectomyCK19, cytokeratin 19FGF19, fibroblast growth factor 19Gallbladder volumeHPLC-MS/MS, high-performance liquid chromatography coupled to tandem mass spectrometryIBD, inflammatory bowel diseaseMagnetic resonance imagingMRC, magnetic resonance cholangiographyPSC, primary sclerosing cholangitisUDCA, ursodeoxycholic acidULN, upper limit of normal

Identifiers

PMID36923239
PMCPMC10009728
OpenAlexW4312083930

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read27
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.